Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this year or early next year unrealistic?
Sounds good
I'm not surprised that people don't want to hold a stock for a month. I wish I would of took advantage of this
Ask is 225 because you can't put in an order right now. Those orders were probably in before the r/s
it's showing .0001 in the 52 week range in ihub also
I've been holding for years. I'll try to stay patient until 2017.
there was a trade today for 32,000 shares at .0001
incredible someone got shares at .0001!?
I thought by September was the timeframe
It's Friday night!
Etrade charged me $20 for this since I only own 5 shares. I don't know why I still own this smh
I don't think it's a good to keep forecasting news but it got me some cheap shares today.
my first time hearing of them
http://www.dailypolitical.com/2016/07/27/innovus-pharmaceuticals-inc-innv-upgraded-to-hold-by-zacks-investment-research-2/
Zacks Investment Research upgraded shares of Innovus Pharmaceuticals Inc (NASDAQ:INNV) from a sell rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “
Shares of Innovus Pharmaceuticals (NASDAQ:INNV) traded down 2.000% during trading on Tuesday, hitting $0.588. The stock had a trading volume of 1,320,002 shares. The stock’s 50 day moving average price is $0.26 and its 200-day moving average price is $0.13. Innovus Pharmaceuticals has a one year low of $0.03 and a one year high of $0.66. The stock’s market cap is $43.03 million.
$INNV Boom!
I surprised this hasn't taken off now that its out in Japan
http://www.forbes.com/sites/olliebarder/2016/07/21/pokemon-go-is-finally-released-in-japan/#41342d9e7588
$INNV flippers have moved on to the next one
nice bounce!
especially for whoever got those shares at .17
cheap shares for sale
$CTDT interesting article http://www.racked.com/2016/6/14/11872830/lab-grown-diamonds-synthetic
I cringed at that comment about a 2 month delay the other day. I don't know how much ihub has an effect on the market but I had a feeling it wasn't good.
Well I bought some this morning at .23 and i'm about to buy more
.10? someone sold everything today possibly
someone got lucky and scored shared for .13!
EmergingGrowth.com Announces Availability of Centaurus Diamond Technology, Inc.; Goldman Research Report $1.05 Price Target
http://www.broadwayworld.com/bwwgeeks/article/EmergingGrowthcom-Announces-Availability-of-Centaurus-Diamond-Technology-Inc-Goldman-Research-Report-105-Price-Target-20160518
MIAMI, FL - EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, today announced that the availability of the Centaurus Diamond Technology, Inc. (OTC PINK: CTDT) Goldman Research Report containing a price target of $1.05 per share.
The Report further states that Goldman can forecast financial data for the next 3 years on a preliminary basis. With AIM Sales commencing in Q2, and diamond sales starting late in the year, they believe that CTDT can generate $1 million in revenue for 2016 and $7 million in 2017. Goldman further stated that for 2018, they preliminarily forecast $40 million in sales, which could be conservative given the industry demand.
The full report can be viewed by visiting EmergingGrowth.com or by the following link:
http://emerginggrowth.com/2016/05/15/centaurus-diamond-technology-inc-otc-pink-ctdt-goldman-price-target/
The report further highlights recent corporate strategy under the guidance of, among others, the recently appointed President/CEO Brian Lauzon, and Chief Scientist Alvin Snaper.
Mr. Lauzon has over thirty-five years of experience in the consumer goods and pharmaceutical industries; from 1993 to 2002, he served as the President of various Mars Inc. subsidiaries with responsibilities for the operations in the United States, Canada, Singapore, Australia and New Zealand. He was responsible for double-digit growth in revenue and profits with some of the most powerful brands in the world, including M&M's, Snickers, Skittles, Twix, Trident gum, Hall's cough drops, Rolaid's, Listerine, Pedigree pet food and Uncle Ben. Under Brian's leadership, Far-East sales grew exponentially. It is notable to mention that he is the innovator of a number of product-sized variations which led to increased market penetration, and he has a proven track record of taking a company's vision and translating it into a consumer want and need. His success rate for new products introduced throughout the world is in excess of 80%. Prior to joining Mars Inc., Brian held senior executive positions at Warner Lambert and TJ Lipton. Brian has extensive experience in Management and Automation and was responsible for building a number of factories for Mars Inc. and Warner Lambert for their Global Operations.
Mr. Snaper serves as Chairman and Chief Scientist of Centaurus Technologies, overseeing all technical aspects related to "cultured" diamond production. In addition to holding patents and modifying existing technologies for laboratory-grown diamonds, and diamond material-based fabrication for the Electronics, Semi-Conductor, Film and Coating Industries, Mr. Snaper is the developer of the Company's proprietary technologies for the production of "cultured" diamond.
Throughout his illustrious career, Mr. Snaper has founded numerous companies and held management and engineering positions at; Neo-Dyne Research Inc., where he served as founder and developed and perfected products bases on his patents; at Advanced Patent Technology Inc. where he served as Vice President Director Research Corporate Director; at an Independent Consulting Firm where he served as founder and became the first multi-technology Registered Engineer licensed in California; at McGraw Colorgraph where he was responsible for overseeing all foreign and domestic testing of photographic systems; and at Bakelite Division of Union Carbide where he assisted in the development of a pilot plan for plastics manufacture.
I've been holding almost 4 years. Also, you should know the risks of investing in penny stocks. Still happy with my decision. CTDT
Man this is the first time my etrade account has been green in years. Finally picked a good one.
CTDT
Centaurus Diamond Technologies, Inc. Upgrades Design of Tooling and Equipment for Magnetic Pulse
LAS VEGAS, Feb. 23, 2016 (GLOBE NEWSWIRE) -- The new Board of Directors and Management Team of Centaurus Diamond Technologies, Inc. (The ‘Company’ or ‘Centaurus Diamond Technologies’ or ‘Centaurus’) (OTCPINK:CTDT) are pleased to announce that the Company has entered the final phase of its proprietary Magnatek process, wherein specifications and guidelines are established for the commercial mass production of industrial diamonds.
Furthermore, we are proud to announce the expansion of our research and development team with the addition of Dr. Igor A. Levitsky. He has over 20 years of experience in technology development, experimental and theoretical study of physical/chemical properties of organic and composite materials including nano-carbons (carbon nanotubes, fullerenes, graphene), organic-inorganic nano-composite, ionomeric polymers, liquid crystals, and molecular aggregates.
Dr. Levitsky has a Ph.D. in Physics (1995), from the Institute for Low Temperature Physics and Engineering, Kharkov, Ukraine, and an M.S. in Physical Optics in 1991 from the Department of Physics, Kharkov State University, Kharkov, Ukraine. He had a postdoctoral appointment at the Chemistry Department at Massachusetts Institute of Technology (1997-1999).
Dr. Levitsky is the founder and Vice President of Emitech, Inc. (www.emitechinc.com) and Corish, Inc. (subsidiary of Emitech); both are high-tech companies in the field of material science and nanotechnology.
Since 1999, Dr. Levitsky has been actively involved in R&D, including the SBIR program, when he worked as a Senior Scientist at the Altair Center (Shrewsbury, MA, 1999-2001) and as a Principal Scientist at Emitech, Inc. (Fall River, MA, 2002- present) and Corish, Inc. (Fall River, MA, 2014-present). As a Principal Investigator, he had multiple SBIR Phase I and Phase II awards (more than fifteen) from different government agencies such as DoD, DoE, NSF, DHS, and DoS (total amount received from the government grants is more than 5 million dollars). Most of these topics were related to the study of organic/inorganic nano-composites and applications of new scientific concepts to the development of novel nano-materials and opto-electronic devices: transparent conductive coating; nano-composite/hybrid solar cells; carbon nanotubes based photo-detectors, photo/electromechanical actuators; field effect transistors; and opto-chemical sensors based on photonic crystals.
Dr. Levitsky has more than sixty publications in peer-reviewed journals, nine patents and many presentations at local and international conferences (including invited talks). He is co-author of a book and two reviews related to carbon nanotubes (CNTs), CNT composites and porous silicon nano-composites for solar cells, photo-detectors, and chemo-sensors.
Dr. Levitsky is a member of the Material Research Society, reviewer for Nature Nanotechnology, Advanced Materials, ACS Nano, Applied Physics Letters, and other highly rated scientific journals. He is member of editorial board of the Journal Nano-medicine and Nanotechnology, the Journal of Nano-materials & Molecular Nanotechnology and the Journal of Solar Energy. Dr. Levitsky' s representative publications/patents can be found at www.emitechinc.com.
The proposed scope of work related to a new material synthesis and characterization is as follows:
Synthesis:
The graphite is an initial material for synthesis of expected new structures under high pulse pressure. However, a variety of nano-carbons can be utilized instead of the graphite, reasonably assuming that the outcome compound could depend on carbon atom organization in the initial material. Nano-carbons materials include:
• Carbon nanotubes (single-walled, multi-walled, functionalized with different groups, peapods, etc.)
• Fullerenes ( C60, C70, C84, others)
• Graphene
Material characterization:
Several methods can be employed for material characterization in order to determine the structural changes from amorphous (graphite) to quasi-ordered or ordered morphology.
• SEM/TEM (scanning electron transition electron micro scopy)
• SAXS (small angle X-ray scattering)
• High resolution optical imaging (x 1000)
• IR spectroscopy (FTIR)
In particular, using our FTIR spectrometer (Tenzor 27) IR spectra of initial (graphite, nano-carbons) and novel material can be recorded and compared. It is expected that ordered morphology should result in appearance of new specific bands in mid-IR similar to the diamond spectrum, while graphite spectrum has no bands in the same spectral range.
The following equipment and facilities are available to our Research and Development Team with the addition of Dr. Igor Levitsky:
Emitech, Inc. and Corish, Inc. have processing/analytical/optical/electronic equipment, which includes: Wet electrochemical etching station for fabrication of porous Si (PSi) photonic crystals (equipped with Keithley-238 and controlled by LabVIEW custom software) allowing us to fabricate various nano-porous structures, such as Micro-cavities, Bragg Reflectors, Rugate filters, with pore diameter in the range from 3-5 nm to 0.5- 1 microns; Programmable furnace (up to 1100 C) for oxidation of PSi structures; Spray-deposition station equipped with a digital air dispenser (EFD, Performus II), airbrushes (Badger Air-Brush Co); Hot plate with regulated surface temperature and in-situ control of the film thickness; and high speed centrifuge. We also have power meters, a mono-chromator, CCD spectrometers, FTIR spectrometer (Bruker, Tensor27) optical benches, and other optical parts and accessories, high precision source-measurement units/multimeters (Keithley 236/238/2000), digital/analog oscilloscopes, lock-in amplifiers, data acquisition systems, LabVIEW and TestPoint software and interfaces for data exchange/processing, function generators, spectrum analyzers, power sources, small area solar simulator, etc. In addition, Emitech/Corish has access to the equipment and instruments at Advanced Technology and Manufacturing Center (ATMC, Fall River, MA), which include SEM, DSC, TGA, optical microscopy, surface engineering and bake tool, surface profilometer, spatterer, etc. (See more at www.atmc.umassd.edu/researchandlabs).
His addition to our Research and Development team will greatly assist the Company in driving the evolution and to help to expedite the final phase of the R&D to reach production milestones.
Throughout the experimental process, it is the Company’s goal to master the exact methodology of mass-producing diamonds and thus obtain the specifications that can assure maximum efficiency of the Magnatek Diamond Synthesis process. Once that is achieved, we will ramp up manufacturing of the Magnatek technology and apparatus to fully automate the process. The facility is already ISO-9002 compliant and it is anticipated to go into full production by the end of 2016.
About Centaurus Diamond Technologies, Inc.
Centaurus has been established to fully commercialize its proprietary, cost-efficient and high-volume diamond production method to provide industrial quality diamonds. The Company's patented technology enables the production of "cultured" diamonds that are chemically, atomically and structurally identical to natural diamonds. The Gemological Institute of America has tested the Company's "cultured" diamonds and has confirmed they are diamonds according to their testing protocols.
Safe Harbor Statement?:
This press release may contain certain "Forward-looking statements" relating to the business of Centaurus Diamond Technologies, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For more information,
contact Chas Radovich, Executive Vice President Investor Relations,
Centaurus Diamond Technologies, Inc. at 714-323-1110
or visit us at http://www.centaurustechnologiesinc.com.
http://globenewswire.com/news-release/2016/02/23/813134/0/en/Centaurus-Diamond-Technologies-Inc-Upgrades-Design-of-Tooling-and-Equipment-for-Magnetic-Pulse.html
nice bounce .0021 $ADMD
I have that problem on mobile app
my whole order didn't fill
in at .0022 today looks good so far $ADMD
I regret not averaging down while holding for more than two years and it was a penny for most of that time but I'm green right now
anyone have a link to the news? and can we sticky it?
I think it's because of the average amount of posts on the board
check out CTDT
take a look at CTDT
Nice! Patience paying off